肿瘤细胞治疗研究
英文原题：Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
近年来，血液系统恶性肿瘤的治疗格局取得了显著进展，尤其是自2017年自体CAR-T 细胞疗法首次获批用于复发/难治性急性淋巴细胞白血病（ALL）以来。
近年来，血液系统恶性肿瘤的治疗显著进步，尤其是 2017 年首次批准自体CAR-T 细胞疗法用于复发/难治性急性淋巴细胞白血病（ALL）以来。自体 CAR-T 疗法通过基因改造患者自身 T 细胞，使其特异性识别并攻击癌细胞；双特异性抗体（BsAb）则同时结合癌细胞和免疫细胞，从而触发针对肿瘤的免疫反应。随后多种 CAR-T 疗法和 BsAb 获批，革新了多种血液系统恶性肿瘤的治疗，并显示出较高缓解率，且一部分患者实现持久疾病控制。本综述探讨自体 CAR-T 疗法及 BsAb 的作用机制，重点介绍其在多发性骨髓瘤、ALL 和非霍奇金淋巴瘤中的临床应用。我们全面分析各疗法的疗效、广泛应用所面临的局限，以及联合治疗的潜力。即将出现的这些策略旨在推动该领域发展，为血液系统恶性肿瘤带来更安全、更有效的治疗干预。
In recent years, the therapeutic landscape for hematological malignancies has markedly advanced, particularly since the inaugural approval of autologous chimeric antigen receptor T cell (CAR-T) therapy in 2017 for relapsed/refractory acute lymphoblastic leukemia (ALL). Autologous CAR-T therapy involves the genetic modification of a patient's T cells to specifically identify and attack cancer cells, while bispecific antibodies (BsAbs) function by binding to both cancer cells and immune cells simultaneously, thereby triggering an immune response against the tumor. The subsequent approval of various CAR-T therapies and BsAbs have revolutionized the treatment of multiple hematological malignancies, highlighting high response rates and a subset of patients achieving prolonged disease control. This review explores the mechanisms underlying autologous CAR-T therapies and BsAbs, focusing on their clinical application in multiple myeloma, ALL, and non-Hodgkin lymphoma. We provide comprehensive insights into their individual efficacy, limitations concerning broad application, and the potential of combination therapies. These upcoming strategies aim to propel the field forward, paving the way for safer and more effective therapeutic interventions in hematological malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
